Adial Pharmaceuticals (Nasdaq: ADIL) reported that its Compensation Committee granted a stock option to a new employee to purchase 307,814 shares of common stock as an employment inducement. The option has an exercise price of $5.76 per share, equal to the August 19, 2026 closing price, and a 10-year term.
The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments, subject to continued service. According to Adial, the option was granted outside existing equity plans under Nasdaq Listing Rule 5635(c)(4), which allows employment inducement grants without shareholder approval but requires public disclosure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.